ArticleInternational journal of pediatric otorhinolaryngology2019
Long-term hearing outcomes of children with symptomatic congenital CMV treated with valganciclovir.
Article in International journal of pediatric otorhinolaryngology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Congenital CMV and Hearing Loss-How Does it Happen and How to Prevent it.Reviews in medical virology · 2026Review
- Long-Term Outcomes in Children With Congenital Cytomegalovirus Infection.Laryngoscope investigative otolaryngology · 2026Article
- Auditory and Vestibular Involvement in Congenital Cytomegalovirus Infection.Pathogens (Basel, Switzerland) · 2024Review
- Congenital Cytomegalovirus Severity Definitions and Treatment Decisions around the World: A Systematic Scoping Review of the Literature.Journal of clinical medicine · 2024Article
- Review
- Treatment of congenital cytomegalovirus infection.Clinical and experimental pediatrics · 2023Article
- Role of Valganciclovir in Children with Congenital CMV Infection: A Review of the Literature.Children (Basel, Switzerland) · 2023Review
- Congenital Cytomegalovirus Screening in Massachusetts Birth Hospitals: A Statewide Survey.International journal of neonatal screening · 2022Article
- Oral Valganciclovir Therapy in Infants Aged ≤2 Months with Congenital Cytomegalovirus Disease: A Multicenter, Single-Arm, Open-Label Clinical Trial in Japan.Journal of clinical medicine · 2022Article
- Progressive, Long-Term Hearing Loss in Congenital CMV Disease After Ganciclovir Therapy.Journal of the Pediatric Infectious Diseases Society · 2022Article
- Murine Models of Central Nervous System Disease following Congenital Human Cytomegalovirus Infections.Pathogens (Basel, Switzerland) · 2021Review
- Economic assessments of the burden of congenital cytomegalovirus infection and the cost-effectiveness of prevention strategies.Seminars in perinatology · 2021Review
- Congenital Human Cytomegalovirus Infection Inducing Sensorineural Hearing Loss.Frontiers in microbiology · 2021Review
- Future directions for screening and treatment in congenital hearing loss.Precision clinical medicine · 2020Article
- Advances in Inner Ear Therapeutics for Hearing Loss in Children.Current otorhinolaryngology reports · 2020Article
- Audiologic Status of Children with Confirmed Cytomegalovirus Infection: a Case Series.Journal of Korean medical science · 2020Article
- AMMI Canada: Response to FAQs about the management of children with congenital cytomegalovirus infection in Canada.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2019Article
- The Role of Antioxidants in the Treatment of Congenital CMV-Related Hearing: A Case-Control Study.OTO openArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectivesCongenital human cytomegalovirus (cCMV) is a leading cause of pediatric hearing loss. Recent literature has suggested that valganciclovir (VGCV) therapy can improve hearing outcomes. The objective of this study was to evaluate the long-term hearing outcomes among symptomatic CMV patients treated with VGCV.
methodsA retrospective chart review of symptomatic CMV patients treated with VGCV was completed. The primary endpoint was the change in best ear hearing scores prior to treatment and after follow-up audiograms. A paired-sample t-test was used to evaluate the data.
resultsA total of 16 children were included in the study and participants were followed for an average of 3.2 years. There was a measurable worsening, but not a statistically significant change in the best ear hearing scores, where the mean change was 11.9 dB (p-value = 0.070). However, 14/16 patients (87.5%, p-value<0.001) were found to have clinically significant worsening of hearing. The mean change in hearing scores for the left and right ear was 14.2 dB (p-value = 0.023) and 15.5 dB (p-value = 0.032), respectively. Mean elapsed time for progressive loss was 2.6 ± 0.2 years. When comparing the better or worse ear, there was no pattern for which ear deteriorated earlier or more frequently.
conclusionsOur data did show a measurable, but not a statistically significant worsening outcome in best ear hearing. There was a significant change in both left and right ear hearing. Our results suggest that VGCV may provide only a short-term improvement in hearing outcomes; however, these preliminary post-hoc findings suggest the need for a more rigorous evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.